A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization
The SARS-CoV-2 pandemic has challenged researchers at a global scale. The scientific community's massive response has resulted in a flood of experiments, analyses, hypotheses, and publications, especially in the field of drug repurposing. However, many of the proposed therapeutic compounds obtained from SARS-CoV-2 specific assays are not in agreement and thus demonstrate the need for a singular source of COVID-19 related information from which a rational selection of drug repurposing candidates can be made. In this paper, we present the COVID-19 PHARMACOME, a comprehensive drug-target-mechanism graph generated from a compilation of 10 separate disease maps and sources of experimental data focused on SARS-CoV-2/COVID-19 pathophysiology. By applying our systematic approach, we were able to predict the synergistic effect of specific drug pairs, such as Remdesivir and Thioguanosine or Nelfinavir and Raloxifene, on SARS-CoV-2 infection. Experimental validation of our results demonstrate that our graph can be used to not only explore the involved mechanistic pathways, but also to identify novel combinations of drug repurposing candidates.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Scientific reports - 11(2021), 1 vom: 26. Mai, Seite 11049 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Schultz, Bruce [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 09.06.2021 Date Revised 01.11.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41598-021-90296-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM325889430 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM325889430 | ||
003 | DE-627 | ||
005 | 20231226203052.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41598-021-90296-2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1086.xml |
035 | |a (DE-627)NLM325889430 | ||
035 | |a (NLM)34040048 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Schultz, Bruce |e verfasserin |4 aut | |
245 | 1 | 2 | |a A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.06.2021 | ||
500 | |a Date Revised 01.11.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The SARS-CoV-2 pandemic has challenged researchers at a global scale. The scientific community's massive response has resulted in a flood of experiments, analyses, hypotheses, and publications, especially in the field of drug repurposing. However, many of the proposed therapeutic compounds obtained from SARS-CoV-2 specific assays are not in agreement and thus demonstrate the need for a singular source of COVID-19 related information from which a rational selection of drug repurposing candidates can be made. In this paper, we present the COVID-19 PHARMACOME, a comprehensive drug-target-mechanism graph generated from a compilation of 10 separate disease maps and sources of experimental data focused on SARS-CoV-2/COVID-19 pathophysiology. By applying our systematic approach, we were able to predict the synergistic effect of specific drug pairs, such as Remdesivir and Thioguanosine or Nelfinavir and Raloxifene, on SARS-CoV-2 infection. Experimental validation of our results demonstrate that our graph can be used to not only explore the involved mechanistic pathways, but also to identify novel combinations of drug repurposing candidates | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a remdesivir |2 NLM | |
650 | 7 | |a 3QKI37EEHE |2 NLM | |
650 | 7 | |a Adenosine Monophosphate |2 NLM | |
650 | 7 | |a 415SHH325A |2 NLM | |
650 | 7 | |a Raloxifene Hydrochloride |2 NLM | |
650 | 7 | |a 4F86W47BR6 |2 NLM | |
650 | 7 | |a GTP Phosphohydrolases |2 NLM | |
650 | 7 | |a EC 3.6.1.- |2 NLM | |
650 | 7 | |a thioguanosine triphosphatase |2 NLM | |
650 | 7 | |a EC 3.6.1.- |2 NLM | |
650 | 7 | |a Nelfinavir |2 NLM | |
650 | 7 | |a HO3OGH5D7I |2 NLM | |
650 | 7 | |a Alanine |2 NLM | |
650 | 7 | |a OF5P57N2ZX |2 NLM | |
700 | 1 | |a Zaliani, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Ebeling, Christian |e verfasserin |4 aut | |
700 | 1 | |a Reinshagen, Jeanette |e verfasserin |4 aut | |
700 | 1 | |a Bojkova, Denisa |e verfasserin |4 aut | |
700 | 1 | |a Lage-Rupprecht, Vanessa |e verfasserin |4 aut | |
700 | 1 | |a Karki, Reagon |e verfasserin |4 aut | |
700 | 1 | |a Lukassen, Sören |e verfasserin |4 aut | |
700 | 1 | |a Gadiya, Yojana |e verfasserin |4 aut | |
700 | 1 | |a Ravindra, Neal G |e verfasserin |4 aut | |
700 | 1 | |a Das, Sayoni |e verfasserin |4 aut | |
700 | 1 | |a Baksi, Shounak |e verfasserin |4 aut | |
700 | 1 | |a Domingo-Fernández, Daniel |e verfasserin |4 aut | |
700 | 1 | |a Lentzen, Manuel |e verfasserin |4 aut | |
700 | 1 | |a Strivens, Mark |e verfasserin |4 aut | |
700 | 1 | |a Raschka, Tamara |e verfasserin |4 aut | |
700 | 1 | |a Cinatl, Jindrich |e verfasserin |4 aut | |
700 | 1 | |a DeLong, Lauren Nicole |e verfasserin |4 aut | |
700 | 1 | |a Gribbon, Phil |e verfasserin |4 aut | |
700 | 1 | |a Geisslinger, Gerd |e verfasserin |4 aut | |
700 | 1 | |a Ciesek, Sandra |e verfasserin |4 aut | |
700 | 1 | |a van Dijk, David |e verfasserin |4 aut | |
700 | 1 | |a Gardner, Steve |e verfasserin |4 aut | |
700 | 1 | |a Kodamullil, Alpha Tom |e verfasserin |4 aut | |
700 | 1 | |a Fröhlich, Holger |e verfasserin |4 aut | |
700 | 1 | |a Peitsch, Manuel |e verfasserin |4 aut | |
700 | 1 | |a Jacobs, Marc |e verfasserin |4 aut | |
700 | 1 | |a Hoeng, Julia |e verfasserin |4 aut | |
700 | 1 | |a Eils, Roland |e verfasserin |4 aut | |
700 | 1 | |a Claussen, Carsten |e verfasserin |4 aut | |
700 | 1 | |a Hofmann-Apitius, Martin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 11(2021), 1 vom: 26. Mai, Seite 11049 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g day:26 |g month:05 |g pages:11049 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-021-90296-2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2021 |e 1 |b 26 |c 05 |h 11049 |